Macquarie Group LTD Denali Therapeutics Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$25.97 - $38.53 $15,036 - $22,308	-579 Reduced 41.03%	832 $72,000
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $1.18 Million - $1.93 Million	-40,750 Reduced 96.65%	1,411 $45,000
Q4 2021 Feb 11, 2022	BUY	$42.59 - $55.02 $10,690 - $13,810	251 Added 0.6%	42,161 $1.88 Million
Q2 2021 Aug 13, 2021	SELL	$50.3 - $78.44 $51,406 - $80,165	-1,022 Reduced 2.38%	41,910 $3.29 Million
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $435,295 - $659,659	8,091 Added 23.22%	42,932 $2.45 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $1.14 Million - $2.9 Million	31,030 Added 814.22%	34,841 $2.92 Million
Q2 2020 Aug 11, 2020	BUY	$16.01 - $28.82 $61,014 - $109,833	3,811 New	3,811 $92,000

237

111M

80K

36.8K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $1.98B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.